e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Asthma biomarkers, diagnostics and risk factors
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Externally validating the asthma remission prediction model to the Dutch asthma remission studies
O. Carpaij (Groningen, Netherlands), J. Vonk (Groningen, Netherlands), M. Nawijn (Groningen, Netherlands), H. Kerstjens (Groningen, Netherlands), G. Koppelman (Groningen, Netherlands), M. Van Den Berge (Groningen, Netherlands)
Source:
International Congress 2019 – Asthma biomarkers, diagnostics and risk factors
Session:
Asthma biomarkers, diagnostics and risk factors
Session type:
Thematic Poster
Number:
4512
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Carpaij (Groningen, Netherlands), J. Vonk (Groningen, Netherlands), M. Nawijn (Groningen, Netherlands), H. Kerstjens (Groningen, Netherlands), G. Koppelman (Groningen, Netherlands), M. Van Den Berge (Groningen, Netherlands). Externally validating the asthma remission prediction model to the Dutch asthma remission studies. 4512
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Association between asthma control trajectories in preschoolers and disease remission
Source: Eur Respir J, 57 (5) 2001897; 10.1183/13993003.01897-2020
Year: 2021
Dyspnoea perception during clinical remission of atopic asthma
Source: Eur Respir J 2002; 20: 1613
Year: 2002
Age at asthma diagnosis and probability of remission in a population-based study
Source: Virtual Congress 2020 – Diagnosis and management of asthma
Year: 2020
Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study
Source: International Congress 2017 – Monitoring asthma control
Year: 2017
Childhood factors associated with complete and clinical asthma remission at 25 and 49 years
Source: Eur Respir J, 49 (6) 1601974; 10.1183/13993003.01974-2016
Year: 2017
Variability and lack of predictive ability of asthma end-points in clinical trials
Source: Eur Respir J 2002; 20: 1102-1109
Year: 2002
Based on what parameters of clinical remission should inhaled corticosteroids be stopped in children with asthma?
Source: Annual Congress 2013 –The best of paediatric asthma and allergy
Year: 2013
Towards a cure for asthma
Source: International Congress 2017 – The Lancet commission on asthma
Year: 2017
Development of a novel prediction model for acute asthma exacerbation
Source: International Congress 2018 – Asthma management
Year: 2018
A predictive model of failed stepping-down of inhaled corticosteroids in adult asthmatics
Source: International Congress 2016 – Notable abstracts on clinical problems related to asthma
Year: 2016
Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
Clinical features and functional parameters predict the probability of ACO in patients with asthma and COPD
Source: International Congress 2018 – Airway disease: recent discoveries
Year: 2018
Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study
Source: International Congress 2017 – Asthma management
Year: 2017
Pharmacoepidemiological analysis of the treatment of bronchial asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 683s
Year: 2005
Childhood obesity in relation to poor asthma control and exacerbation: a meta-analysis
Source: Eur Respir J 2016; 48: 1063-1073
Year: 2016
Comparative assessment of asthma control test and GINA classification in predicting asthma severity
Source: Annual Congress 2007 - Airway regulation, provocation and monitoring II
Year: 2007
Asthma patients adjust their maintenance treatment late in response to worsening asthma symptoms
Source: Eur Respir J 2005; 26: Suppl. 49, 7s
Year: 2005
Bronchodilator reversibility in asthma and COPD: findings from three large population studies
Source: Eur Respir J, 54 (3) 1900561; 10.1183/13993003.00561-2019
Year: 2019
Mathematical model to predict the risk of future exacerbations in non-smoking patients with COPD
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept